Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.
Epistemonikos ID: 916858fb0aef04080fcf707faae6dcd1da84fea5
First added on: May 07, 2024